Tranzyme, Inc. Report issue

For profit Phase 2 Phase 3
Founded: Durham NC United States (1998)
Status: Acquired by Ocera Therapeutics (2013) → now Mallinckrodt (2013) (2017)

Organization Overview

First Clinical Trial
2006
NCT00639808
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Tranzyme Pharma

Active Ingredients

Drugs in Phase 3 Trials (2)

glucose monohydrate (5 trials)

ulimorelin (5 trials)

Drugs in Phase 2 Trials (1)

tzp-102 (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 1 (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Gastroparesis (Phase 2)

Ileus (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 3